Radiomic fEatures of Pancreas From Contrast Enhanced CT Image Predict One-Year RecUrrence Risk of… (NCT05778929) | Clinical Trial Compass
UnknownNot Applicable
Radiomic fEatures of Pancreas From Contrast Enhanced CT Image Predict One-Year RecUrrence Risk of Acute PancReatitis
694 participantsStarted 2023-04-01
Plain-language summary
One-year recurrence rate of acute pancreatitis at about 20%. 36% of the patients with recurrent acute pancreatitis will develop into chronic pancreatitis. In addition to negative impact on patient's quality of life, chronic pancreatitis is also associated with the occurrence of pancreatic cancer. The etiology of recurrent acute pancreatitis (RAP) can be divided into mechanical obstructive factors (e.g. cholelithiasis, cholestasis), metabolic abnormality and toxic substance factors (e.g. hyperlipidemia and alcoholism), and other or idiopathic factors. At present, the diagnosis and treatment of RAP remains highly challenging. Early identification and intervention on risk factors of recurrence will be effective in reducing incidence and improving prognosis.
Contrast-enhanced Computed Tomography (CT) can not only provide more imaging information and further assess the severity of acute pancreatitis, but also aid in the differentiation of other diseases associated with acute abdominal pain. In addition, radiomics based on raw radiographic data has become a research hotspot in recent years. The purpose of this study is to establish and validate a deep learning model based on high concentration iopromide-enhanced abdominal CT images which is designed to predict the recurrence of pancreatitis in patients with first episode of pancreatitis within the 1-year follow-up period.
Who can participate
Age range
18 Years – 70 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. 18 -70 years old
. The subject met the following three criteria and diagnosed with acute pancreatitis according to the Atlanta Classification of Acute Pancreatitis.
.1 Abdominal pain indicative of pancreatitis 2.2 Serum levels of amylase or lipase \>3 times the upper limit of normal 2.3 Characteristic findings from abdominal imaging (unenhanced CT\\MR\\ultrasonography)
. Referred for an enhanced CT examination with Iopromide 370 in 14 days after symptom onset by clinicians
. Sign the informed consent
Exclusion criteria
. Has history of allergy to iodinated contrast agent
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This study is looking at CT scan features to predict whether acute pancreatitis will come back within a year — does my current situation, including how recently I had an episode, make this kind of imaging analysis relevant to my care?
2Since this trial seems to be building a predictive model rather than testing a treatment, what would actually happen to me as a participant — would I just have a CT scan reviewed, or would there be additional procedures or follow-up visits involved?
3The study's recruitment status is listed as unknown — can you find out whether this trial is still actively enrolling patients, and if not, are there similar observational studies I could join instead?
4If the model this study is developing turns out to be accurate, how might knowing my one-year recurrence risk actually change the treatment or monitoring plan you'd recommend for me?
5Given that this is a non-treatment observational study, would participating in it delay or interfere with any standard care options I should be considering right now for my pancreatitis?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
The sensitivity and specificity of the model established with relevant clinical factors and radiomic features